FDA Approves R21 Malaria Vaccine Considered ‘World-Changer’

The Food and Drugs Authority (FDA) has given market authorisation to a new malaria vaccine – R21. The vaccine was developed by Oxford University and manufactured by the Serum Institute of India. The FDA says after a thorough evaluation of the quality, efficacy, and safety of the vaccine, they realized that the benefits far outweigh the risks. Briefing the media on Thursday, the CEO of the FDA, Dr. Delese Darko says they have approved the vaccine’s use in children between the ages of five months to three years. “On March 28 this year, the FDA granted approval to R21 malaria…